載入中
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$8.42
+US$0.25 · +3.06%
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
前收盤價
US$8.42
+US$0.25 · +3.06%
盤中時間採用ET。市場資料可能有所延遲。
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
日內區間
目前US$8.42
52週區間
目前US$8.42
盤中時間採用ET。市場資料可能有所延遲。
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
日內區間
目前US$8.42
52週區間
目前US$8.42
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6657.5萬 USD | 5564.1萬 USD | 5254.8萬 USD | 4556.3萬 USD | 4829.9萬 USD |
| 銷貨成本 | 2777.6萬 USD | 2252.9萬 USD | 2309.2萬 USD | 2421.4萬 USD | 2058.8萬 USD |
| 毛利 | 3879.9萬 USD | 3311.2萬 USD | 2945.6萬 USD | 2134.9萬 USD | 2771.1萬 USD |
| 研究與開發 | 625.4萬 USD | 537.5萬 USD | 486.5萬 USD | 987.6萬 USD | 723.7萬 USD |
| 銷售、一般及管理費用 | 4661.5萬 USD | 4137.3萬 USD | 4742.8萬 USD | 5201.8萬 USD | 4454.1萬 USD |
| 營業費用 | 5286.9萬 USD | 4674.8萬 USD | 5229.3萬 USD | 6740萬 USD | 5177.8萬 USD |
| 利息收入 | 28.9萬 USD | 76.7萬 USD | 151.6萬 USD | 83萬 USD | 1.6萬 USD |
| 利息支出 | 431.8萬 USD | 223.4萬 USD | 233.5萬 USD | 244.8萬 USD | 262.5萬 USD |
| 折舊和攤銷 | 211.8萬 USD | 172.4萬 USD | 216.8萬 USD | 155.7萬 USD | 94.8萬 USD |
| 營業利益 | −1407萬 USD | −1363.6萬 USD | −2283.7萬 USD | −4605.1萬 USD | −2406.7萬 USD |
| 淨利 | −1995.1萬 USD | −1511.5萬 USD | −2368.9萬 USD | −4738.7萬 USD | −2685.1萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$8.00
下跌空間 4.99%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI304.5萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF139.82萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC35.95萬0.03%13.17億 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM21萬0.18%1.17億 USD0.73%US$15.9402+0.25%
Invesco NASDAQ Future Gen 200 ETFQQQS13.76萬0.60%2275.83萬 USD0.20%US$42.145+1.39%
Dimensional - US Core Equity 2 ETFDFAC5.32萬0.00%885.96億 USD0.21%US$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco NASDAQ Future Gen 200 ETFQQQSDimensional - US Core Equity 2 ETFDFACAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
